Navigation Links
New Treatment Rivals Chemotherapy For Lymphoma, Study Finds

The future of cancer treatment - targeted radiotherapy, on a cellular scale. Antibodies coupled to radioactive isotopes specifically seek out, bind to and kill cancerous cells. Provided that you can find something different on the cell surface between normal and cancerous cells; this is not as easy as it sounds.

A new form of treatment for lymphoma that takes a fraction of the time of traditional chemotherapy with fewer side effects caused tumors to shrink in 95 percent of patients, a new study by researchers at the University of Michigan Comprehensive Cancer Center found.

Patients with advanced-stage follicular lymphoma ?a cancer generally considered incurable ?who had not been previously treated with any other form of therapy received a single course of treatment with the Bexxar therapeutic regimen, a radioactive antibody injected into the bloodstream that targets and kills cancer cells. Of the 76 patients enrolled in the study, 95 percent responded to the treatment and 75 percent had a complete response, meaning no evidence of cancer remained. More than three-quarters of patients with a complete remission were disease-free after five years.

Results of the study appear in the Feb. 3 New England Journal of Medicine.

"The results of this treatment, which essentially takes only one week to complete, rival any kind of treatment that's been used for follicular lymphoma, including chemotherapy regimens that take months to complete. It's very well-tolerated by patients and we saw complete remission in the majority of patients lasting for years," says lead study author Mark Kaminski, M.D., director of the Leukemia/Lymphoma Program and the Multidisciplinary Lymphoma Clinic at the U-M Comprehensive Cancer Center.

Kaminski and his colleague Richard Wahl (formerly at U-M and now at Johns Hopkins University) developed the Bexxar regimen, which received approval from the U.S. Food and Drug Administration in June 2003 to treat foll
'"/>

Source:University Of Michigan Health System


Page: 1 2 3

Related biology news :

1. Discovery Could Lead To Novel Approaches In HIV Treatment
2. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
3. Effective Cancer Treatments Follow The Clock
4. Protein Discovery Could Unlock The Secret To Better TB Treatment
5. Natural Killers Could Lead to New Hepatitis Treatments
6. FDA Approves New Treatment for Chronic Hepatitis B
7. Study Finds Moderate Hypothermia A Safe Treatment For Traumatic Brain Injury In Kids
8. Drug Offers Alternative to Surgical Treatment After Miscarriage
9. Treatments have same target, different responses for lung cancer patients with genetic mutation
10. Minimally Invasive Cancer Treatments Highlighted
11. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer

Post Your Comments:
(Date:11/6/2009)...A (November 06, 2009) The Monell Center and the C...he Beijing International Meeting on Taste and Smel...ith the CAS, the meeting will be the first interna...ina. , Alan Leshner, Chief Executive Officer, Am...and Executive Publisher of Science magazine, will ...
(Date:11/5/2009)...Conn.Researchers at Yale University have developed...,s immune response to HIV and HIV-infected cells, ...s, published online in the Journal of the America...ic approaches for these diseases. , The molecul... HIV" (ARM-H) and "antibody-recruiting molecule ta...
(Date:11/4/2009)...A Although scientists are reluctant to officially...evidence continues to grow about its protective ef...in Cancer Prevention Research , a journal of the ...ggests some reduction in oral cancer. , Vassili... in the Department of Thoracic/Head and Neck Medic...
Breaking Biology News(10 mins):Monell Center joins with CAS to host Beijing meeting on taste and smell research 2New synthetic molecules trigger immune response to HIV and prostate cancer 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2SpectraScience Engages European Contract Research Organization to Manage Clinical Trials 14457 1SpectraScience Engages European Contract Research Organization to Manage Clinical Trials 14457 2SpectraScience Engages European Contract Research Organization to Manage Clinical Trials 14457 3Global Bioenergies is Setting Up its Scientific Advisory Board and Obtains Proof of Concept for a Bioprocess Generating Gaseous Hydrocarbons From Rene 14455 1Global Bioenergies is Setting Up its Scientific Advisory Board and Obtains Proof of Concept for a Bioprocess Generating Gaseous Hydrocarbons From Rene 14455 2Amylin Pharmaceuticals to Webcast Third Quarter Results 14453 1Amylin Pharmaceuticals to Webcast Third Quarter Results 14453 2
...roinformatics will convene September 7-9 at the St...merging neuroinformatics field combines neuroscien...ols and approaches to understanding the structure ...pplied to brain disorders and diseases. With a bro...together experts from all disciplines contributing...
... a sophisticated computer model pioneered at Princ...ound that many governments worldwide are recommend...e the availability of many drugs and therapies to ...ecommend using what is known as a single first-lin...th many patients. Writing in the Sept. 16 issue of...
...eding colonies of a critically endangered vulture,... of millions to a few thousand, are too small to p...f Michigan analysis shows. , Adding wild birds to...ia, is crucial, but political and logistical barri.... Johnson. , The study was published online Augus...
Other Biology News:INCF organizes the first congress dedicated to the emerging field of neuroinformatics 2Best way to treat malaria: Avoid using same drug for everyone, scientists say 2Best way to treat malaria: Avoid using same drug for everyone, scientists say 3Recovery efforts not enough for critically endangered Asian vulture 2Recovery efforts not enough for critically endangered Asian vulture 3
(Date:11/9/2009)..., SCHIEDLBERG, Austria, November 9 /PRNewswi... the world have been working on the development of...t communication channel,between the brain and a co...,patients to communicate or to control devices in ...the last years some patients have been supervised ...
(Date:11/9/2009)... Product release is a resea...ubjects, research facilities and research safety s...n. , Cedar Knolls, NJ (PR...nounced today that it has unveiled Pristima™...r research facilities that track the use and care ...
(Date:11/6/2009)..., TORONTO, Nov. 6 /PRNewswire-FirstCall/ - Micro...y that it has re-filed the Form 52-109F1 Certifica...f Executive Officer and James Long, the Chief Fina... January 12, 2009 in connection with the annual au...ember 30, 2008. ,, The Company initially filed ...
(Date:11/6/2009)..., SAN MATEO, Calif., Nov. 6 /PRNewswire-FirstCal... Completed transfer of Qutenza(TM) E.U. Marketing ...e significant progress in commercial readiness act...les; Senior Director, Marketing; and Director, Com...to board as director and Audit Committee chairman ...
Breaking Biology Technology:intendiX - Communication by Thoughts: First Patient-Ready System on the Market 2Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management 2NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10
...y of grant-winning ability, the University of Wis... National Science Foundation to address some of t...change. , ,The NSF grants, coupled with matching i...ost to the university,s graduate study and researc...onmental protection. , ,The two $3 million grants...
...ng of new products, or simply the last rush to get...ay was a busy day for product news. In fact, two D...tive newcomer Streamload - are delivering signif...s. , ,In the case of Palm, it is the Treo 700p sma...based on a lovely new implementation of the Palm O...
...holder lawsuits alleging violations of federal sec...nologies, Inc. has accepted the resignation of co...rtimore, who founded the company and served as its...en appointed as the company,s interim CEO. Mike Du... named chairman of the board of directors, succeed...
Other Biology Technology:NSF grants bolster integrative graduate study at UW-Madison 2Two DEMO alumni make big product splashes 2Two DEMO alumni make big product splashes 3Merge president steps down in wake of shareholder suits 2Merge president steps down in wake of shareholder suits 3
...ion: 0.15M NaCl, 20mM MOPS, pH 7.5, 60mM 2-mercapt...perites: For selective in vitro dephosphorylation ...alent cation activation plus trypsin digestion, an... routinely evaluated by dephosphorylation of prote...
Anti-Human sVCAM-1 / CD106 ELI-PAIR Kit Antibody, Unconjugated from Cell Sciences
Mouse Anti-GLP-1 Monoclonal Antibody, Unconjugated, Clone HYB 147-12 from Santa Cruz Biotechnology, Inc.
21-mer duplex design + syn.; 1 gene from B-Bridge International
Biology Products: